Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1949 1
1955 2
1979 2
1980 1
1982 2
1983 2
1984 3
1985 1
1986 4
1987 4
1988 4
1989 1
1990 3
1991 1
1992 1
1993 3
1994 4
1996 2
1997 3
1998 2
1999 7
2000 1
2001 1
2003 1
2004 1
2005 4
2006 4
2007 1
2008 2
2011 2
2012 1
2014 1
2015 2
2016 4
2017 8
2018 5
2019 10
2020 4
2021 12
2022 9
2023 5
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Bassetti M, et al. Among authors: echols r. Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058795 Clinical Trial.
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, Kollef M, Menon A, Pogue JM, Shorr AF, Timsit JF, Zeitlinger M, Nagata TD. Wunderink RG, et al. Among authors: echols r. Lancet Infect Dis. 2021 Feb;21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058798 Clinical Trial.
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD. Portsmouth S, et al. Among authors: echols r. Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25. Lancet Infect Dis. 2018. PMID: 30509675 Clinical Trial.
Redefining penems.
Dalhoff A, Janjic N, Echols R. Dalhoff A, et al. Among authors: echols r. Biochem Pharmacol. 2006 Mar 30;71(7):1085-95. doi: 10.1016/j.bcp.2005.12.003. Epub 2006 Jan 18. Biochem Pharmacol. 2006. PMID: 16413506 Review.
Serratia marcescens.
Echols RM. Echols RM. N Engl J Med. 1979 Aug 16;301(7):388. N Engl J Med. 1979. PMID: 379645 No abstract available.
123 results